With consumer power growing in healthcare, it’s time for medical device companies to get serious about putting user needs first.
News & Features
Abbott kicked in for a $55 million financing round to support Bigfoot Biomedical's diabetes management systems.
Smaller, more powerful batteries are needed for implantables and for connectivity, shares a BIOMEDevice Boston speaker.
These two medtech startups have outlasted the competition in our tournament. Which one do you think has what it takes to make it in the real world?
These seven medtech companies aren't just moving the needle, they're getting rid of it all together!
The ongoing TAVR patent dispute between Boston Scientific and Edwards continues, with the former scoring a partial victory over the latter in the U.K. courts.
FDA's milestone decision classifies Dexcom's continuous glucose monitoring (CGM) system as a less-stringent class II medical device that is interoperable with other technologies and enables a speedier review for similar future systems.
Intact Vascular's Tack Endovascular System is an implant for precision dissection repair following balloon angioplasty and could be on the U.S. market with a BTK indication in 2020.
Sofregen wants to use a reverse-engineered form of silk for implantable and injectable aesthetics and medical products.
SetPoint Medical launches 15-patient pilot trial for its miniaturized vagus nerve stimulation device to treat RA.
Edwards scores a victory in an ongoing TAVR patent dispute, but Boston Scientific said it will appeal USPTO's decision.